94 related articles for article (PubMed ID: 25548839)
1. Fields of muscular and anhidrotic effects of 2 botulinum toxin-A commercial preparations: a prospective, double-blind, randomized, multicenter study.
Hexsel D; Soirefmann M; Porto MD; Siega C; Schilling-Souza J; Rodrigues TC
Dermatol Surg; 2015 Jan; 41 Suppl 1():S110-8. PubMed ID: 25548839
[TBL] [Abstract][Full Text] [Related]
2. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
Hexsel D; Brum C; do Prado DZ; Soirefmann M; Rotta FT; Dal'Forno T; Rodrigues TC
J Am Acad Dermatol; 2012 Aug; 67(2):226-32. PubMed ID: 22041253
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
[TBL] [Abstract][Full Text] [Related]
4. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A.
Hexsel D; Dal'Forno T; Hexsel C; Do Prado DZ; Lima MM
Dermatol Surg; 2008 Jan; 34(1):52-9. PubMed ID: 18053050
[TBL] [Abstract][Full Text] [Related]
5. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study.
Kranz G; Haubenberger D; Voller B; Posch M; Schnider P; Auff E; Sycha T
Mov Disord; 2009 Jan; 24(2):231-6. PubMed ID: 18951439
[TBL] [Abstract][Full Text] [Related]
6. Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview.
Rzany B; Ascher B; Monheit G
J Eur Acad Dermatol Venereol; 2010 Jan; 24 Suppl 1():1-14. PubMed ID: 19930409
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
Göbel H; Heinze A; Reichel G; Hefter H; Benecke R;
Pain; 2006 Nov; 125(1-2):82-8. PubMed ID: 16750294
[TBL] [Abstract][Full Text] [Related]
9. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?
Wohlfarth K; Sycha T; Ranoux D; Naver H; Caird D
Curr Med Res Opin; 2009 Jul; 25(7):1573-84. PubMed ID: 19463043
[TBL] [Abstract][Full Text] [Related]
10. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
Kim SB; Ban B; Jung KS; Yang GH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
[TBL] [Abstract][Full Text] [Related]
11. Fields of anhidrotic effects of abobotulinumtoxinA in patients with compensatory hyperhidrosis.
Hexsel D; Soirefmann M; Porto MD; Schilling-Souza J; Siega C
Dermatol Surg; 2015 Jan; 41 Suppl 1():S93-100. PubMed ID: 25548853
[TBL] [Abstract][Full Text] [Related]
12. Effect of botulinum toxin concentration on reduction in sweating: a randomized, double-blind study.
Rystedt A; Karlqvist M; Bertilsson M; Naver H; Swartling C
Acta Derm Venereol; 2013 Nov; 93(6):674-8. PubMed ID: 23694974
[TBL] [Abstract][Full Text] [Related]
13. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections?
Benecke R; Heinze A; Reichel G; Hefter H; Göbel H;
Pain Med; 2011 Nov; 12(11):1607-14. PubMed ID: 21692970
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study.
Kranz G; Paul A; Voller B; Posch M; Windischberger C; Auff E; Sycha T
Br J Dermatol; 2011 Jan; 164(1):176-81. PubMed ID: 21039405
[TBL] [Abstract][Full Text] [Related]
15. Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions.
Kranz G; Sycha T; Voller B; Gleiss A; Schnider P; Auff E
Dermatol Surg; 2006 Jul; 32(7):886-90. PubMed ID: 16875469
[TBL] [Abstract][Full Text] [Related]
16. Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis.
Rystedt A; Swartling C; Färnstrand C; Naver H
Acta Derm Venereol; 2008; 88(5):458-61. PubMed ID: 18779882
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of biological activity of four botulinum toxin type A preparations in mice.
Chung ME; Song DH; Park JH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):155-64. PubMed ID: 23301819
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Comella CL; Jankovic J; Truong DD; Hanschmann A; Grafe S;
J Neurol Sci; 2011 Sep; 308(1-2):103-9. PubMed ID: 21764407
[TBL] [Abstract][Full Text] [Related]
20. Anhidrotic effect of intradermal injections of botulinum toxin: a comparison of different products and concentrations.
Rystedt A; Swartling C; Naver H
Acta Derm Venereol; 2008; 88(3):229-33. PubMed ID: 18480920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
